30 results about "Targeted Radiotherapy" patented technology

Systems and methods for detecting and diagnosing faults in a radiotherapy system, such as a fault related to a dynamic leaf guide (DLG), are discussed. An exemplary predictive maintenance system includes a processor configured to receive machine data indicative of configuration and operation of a DLG in a target radiotherapy machine, apply a trained deep learning model to the received machine data, and detect and diagnose a DLG fault. The predictive maintenance system can train the deep learning model using data sequences constructed from the received machine data of the one more normal DLGs and the one or more faulty DLGs. Diagnosis of the DLG fault in the target radiotherapy machine includes classifying the DLG faults into different fault types or different fault severities.

The invention relates to the technical field of computers, and discloses an automatic segmentation and intelligent plan generation method and device suitable for self-adaptive radiotherapy of prostate cancer. Comprising the following steps: acquiring medical image data of a treated object, clinical dose data of a target area and an organ at risk in a focus area of the treated object, and clinical treatment data of a preset priority level; performing automatic segmentation based on the medical image data to obtain target segmentation data; performing dose distribution prediction according to the target segmentation data to obtain initial dose distribution data, and performing iterative optimization on the initial dose distribution data by using clinical treatment data to obtain target dose distribution data of the treated object; and performing iterative optimization of a radiotherapy plan based on the target dose distribution data, and generating a target radiotherapy plan of the treated object. Therefore, on the basis of realizing accurate, efficient and automatic segmentation of the prostate cancer target region and the endangered organ, multi-round iterative optimization of dose distribution and the radiotherapy plan is carried out, and finally a high-quality target radiotherapy plan is obtained.

The invention relates to a self-adaptive radiotherapy plan determination method, a self-adaptive radiotherapy system and a storage medium. The method comprises the following steps: acquiring a current region-of-interest segmentation result and current image features corresponding to a current image of an object; according to the segmentation result of the current region of interest and the current image features, candidate radiotherapy plans are selected from a plan library of the object, and the plan library comprises historical images of the object and corresponding historical radiotherapy plans; calculating a calculated dose distribution corresponding to the current image based on parameters in the candidate radiotherapy plan; determining the applicability of the candidate radiotherapy plan for the current image according to the calculated dose distribution, the segmentation result of the current region of interest and the features of the current image; and the target radiotherapy plan for the current image is determined based on the applicability, so that the generation efficiency and effectiveness of the adaptive radiotherapy plan are improved.

Methods and kits for mitigating lung injury in a subject treated with a targeted radiation therapy or otherwise exposed to radiation are described. In particular, an effective amount of a thrombopoietin mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the radiation-induced lung injury.

This application discloses a real-time adaptive radiotherapy management system, relating to the field of medical technology. The system includes: a real-time data processing unit for acquiring real-time data of the target object during radiotherapy; an adaptive decision-making unit for determining a target radiotherapy plan matching the current state of the target object from multiple alternative radiotherapy plans based on the real-time data, wherein the multiple alternative radiotherapy plans are associated with different physiological motion phases or anatomical states of the target object; a plan execution sequence splitting unit for parsing and splitting each alternative radiotherapy plan into one or more hardware execution sequences; and an execution scheduling unit for sending at least one hardware execution sequence corresponding to the target radiotherapy plan to the control system of the radiotherapy equipment. This application solves the technical problem that existing adaptive radiotherapy systems, due to their rigid architecture and singular decision-making mode, cannot achieve highly real-time dynamic plan switching during treatment.

This invention discloses a folic acid receptor-targeting compound and its uses, belonging to the field of pharmaceutical technology. The folic acid receptor-targeting compound is a compound of formula (I), its stereoisomer, its crystalline hydrate, its deuterated derivative, its solvate, its prodrug, or a pharmaceutically acceptable salt thereof: [target]-(L x ) s -R x (I), where [target] is a folic acid receptor-binding ligand; R x The chelating group is Ch or the prosthetic group is PG; s is an integer from 1 to 10; L x It contains at least one L 3 and with AA, L 1 L 2 or L 3 Arbitrary combinations are possible. The folic acid receptor-targeting compounds of this invention have low KD values ​​and strong affinity between the ligands and receptors, and can be used as folic acid receptor-targeted radiotherapy agents for imaging, diagnosis, and treatment of folic acid receptor (FR)-expressing tumors or cells.

The disclosed method of treating a malignant solid tumor in a subject comprises the steps of administering to the subject an immunomodulatory dose of a radiophosphatide ether metal chelate, a radiohalogenated phosphatide ether, or other targeted radiotherapy (TRT) agent differentially retained in the malignant solid tumor, and treating the malignant solid tumor by systemically administering an immunostimulatory agent to the subject. Immunotherapy is performed in a subject, such as an immune checkpoint inhibitor. In a non-limiting example, a radioactive phospholipid ether metal chelate or radioactive halogenated phospholipid ether has the formula: # imgabs0 # wherein R1 comprises a chelating agent that chelates with a metal atom wherein the metal atom is an alpha, beta or Auger emitting metal isotope having a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is-N + (CH3) 3.

Disclosed herein is an engineered bacterium comprising a chimeric nucleic acid comprising: a first nucleic acid encoding an ompA protein or a fragment thereof; and a second nucleic acid encoding a radiohapten binding protein. Further disclosed are methods of using these constructs in methods for pre-targeted radiotherapy and for treating tumors.

Disclosed herein are compounds, combinations, and kits that can be used to more quickly remove radionuclides from a subject, preferably a human being. Said compounds, combinations and kits can also be used to increase the tumor-to-blood ratio, or to more rapidly and / or conveniently achieve such an increase, of a label in targeted imaging or targeted radiotherapy in a subject, preferably a human being.

A pharmacological composition contains a complex having a structurally modified RGD polypeptide a radionuclide. This pharmacological composition is useful for diagnosis or treatment of the integrin αvβ3-positive tumors. The pharmacological composition may further contain an immunotherapeutic medicament and an optional nanoantibody molecular imaging probe. Treatment with a PD-L1 blockade after the targeted radioactive therapy can archive the optimal synergic efficacy. Moreover, with administration of PD-1 or PD-L1 nanoantibody molecular imaging probe, expression of PD-1 or PD-L1 in the tumor after targeted radiotherapy can be observed.

The invention provides a close-range radiotherapy template printing data determination method. According to the method, medical image data of a to-be-detected area of a target object is acquired, an original radiotherapy template three-dimensional model is generated according to the medical image data, and then a receptor area and a diffusion area on a source application curved surface are determined according to the receptor curved surface of target tissue in the to-be-detected area; a needle insertion channel set is generated in the original radiotherapy template three-dimensional model, and target radiotherapy template printing data is generated according to the original radiotherapy template three-dimensional model and the needle insertion channel set; therefore, the radiotherapy template formed after the determined radiotherapy template printing data is subjected to three-dimensional printing can utilize the receptor area to realize comprehensive coverage of the current tumor tissue, and can also utilize the diffusion area to realize prediction matching of tumor tissue edge development. The complex process of repeatedly sampling medical images and manufacturing radiotherapy templates is effectively avoided.

Example methods and systems for deep transfer learning for radiotherapy treatment planning are provided. One example method may comprise: obtaining (310) a base deep learning engine that is pre-trained to perform a base radiotherapy treatment planning task; and based on the base deep learning engine, generating a target deep learning engine to perform a target radiotherapy treatment planning task. The target deep learning engine may be generated by configuring (330) a variable base layer among multiple base layers of the base deep learning engine, and generating (340) one of multiple target layers of the target deep learning engine by modifying the variable base layer. Alternatively or additionally, the target deep learning engine may be generated by configuring (350) an invariable base layer among the multiple base layers, and generating (360) one of multiple target layers of the target deep learning engine based on feature data generated using the invariable base layer.

The present invention relates to compounds of formula (I) that have the potential to be used as metal complexes in radiotherapy. TIFF2024538619000043.tif85132 (wherein A is CO2R 1 , and PO3R 1 and B is selected from the group consisting of COR 2 , and PO3R 2 R 1 , R 2 and R 3 are each independently H and C1 to C 12 alkyl, and each R a is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN; b are independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN, and L is a linker having 1 to 20 atoms in the normal chain), or a pharma- ceutically acceptable salt thereof.

The utility model relates to the field of medical instruments, in particular to a nasal esophageal tracheal fistula three-balloon nasal feeding tube composite set loaded with radioactive particles, which comprises a tube body, a lower blocking balloon, a particle balloon, an upper blocking balloon, a tube body butt joint structure and a nasal guide structure. The radion-loaded three-balloon nasal feeding tube composite set for the nasal esophageal and tracheal fistula is a medical instrument which is combined with the nasal feeding tube and can be used for blocking and treating a fistula opening of a patient suffering from the esophageal and esophageal fistula and carrying out precise targeted radiotherapy on a cancerous part of esophageal cancer, and feeding nutrition of the patient is convenient to convey. The device is simple in structure, convenient to operate, high in working and operating efficiency, stable in operation, beneficial to popularization and promotion, capable of effectively relieving pain of patients, convenient to mount and dismount, obvious in acting effect, capable of achieving differentiated treatment, stable in whole and high in pertinence, and has wide market prospects.

The present invention relates to an inhibitor targeting platelet-derived growth factor receptor β (PDGFRβ), a radioactive probe and their applications, belonging to the fields of nuclear medicine imaging agents and radionuclide radiotherapy agents. The inhibitor of the present invention is at least one of the compounds shown by formula I, and the radioactive probe is at least one of the compounds shown by formula II. The radioactive probe targeting PDGFRβ provided by the present invention can specifically target tumors with high expression of PDGFRβ, and has good tumor uptake and rapid in vivo metabolism properties. The radioactive probe targeting PDGFRβ provided by the present invention has a good tumor-to-background ratio, can be rapidly metabolized and excreted from the body through the kidneys, and has important clinical application value for the early and accurate diagnosis and targeted radiotherapy of PDGFRβ-positive tumors and screening of beneficiaries of anti-angiogenic treatment strategies.

The invention discloses a real-time adaptive radiotherapy management system, and relates to the field of medical science and technology. The system comprises a real-time data processing unit used for acquiring real-time data of a target object in a radiotherapy process; the self-adaptive decision-making unit is used for determining a target radiotherapy plan matched with the current state of the target object from multiple alternative radiotherapy plans of the target object based on the real-time data, and the multiple alternative radiotherapy plans are associated with different physiological motion phases or anatomical states of the target object; the plan execution sequence splitting unit is used for analyzing and splitting each alternative radiotherapy plan into one or more hardware execution sequences; and the execution scheduling unit is used for issuing the at least one hardware execution sequence corresponding to the target radiotherapy plan to a control system of the radiotherapy equipment. The technical problem that an existing adaptive radiotherapy system cannot realize high-real-time dynamic plan switching in the treatment process due to framework stiffness and single decision mode is solved.

Provided herein are methods for treating cancer, including pancreatic cancer, lung cancer, or breast cancer, comprising administering to a subject in need thereof a FAP-targeted radiotherapeutic as a monotherapy or in combination with one or more chemotherapeutic agents.

The invention relates to the technical field of biomedical nano materials, and discloses a targeted radiotherapy sensitizer, a bionic nano delivery system and a preparation method and application of the targeted radiotherapy sensitizer and the bionic nano delivery system. The preparation method of the targeted radiotherapy sensitizer comprises the following steps: dissolving triphenylphosphine and a polypeptide condensing agent in anhydrous DMF (Dimethyl Formamide), and uniformly stirring; then adding an SH-PEG2000-NH2 solution, and carrying out a reaction, so as to obtain SH-PEG2000-TPP (Triphenyl Phosphate); heating and refluxing the chloroauric acid solution, adding a sodium citrate solution, and reacting to obtain an AuNPs dispersion liquid; the preparation method comprises the following steps: mixing an AuNPs dispersion liquid, SH-PEG2000-NH2 and SH-PEG2000-TPP, and carrying out a reaction, so as to obtain AuNP-PEG2000-TPP nanoparticles, namely the targeted radiotherapy sensitizer. After entering tumor mitochondria, the targeted radiotherapy sensitizer disclosed by the invention can effectively absorb ray energy through X-ray irradiation, convert the ray energy into heat energy and electron excitation energy, generate reactive oxygen species (ROS), further activate inflammatory small bodies and caspase-1, then generate N-terminal GSDMD protein fragments, start a pyroptosis process and play a relatively strong radiotherapy sensitization role; proinflammatory cytokines such as IL-1beta and IL-18 are released in the pyroptosis process, and local immune response is further expanded.

The invention provides a probe based on CD206 targeting peptide mUNO as well as a preparation method and application of the probe, and belongs to the technical field of biological medicines. According to the invention, a TAMs-CD206 targeting peptide mUNO is taken as a targeting molecule, and a chelating agent DOTA is coupled through a linking group, so that a bifunctional probe with targeting property and metal nuclide chelating ability is constructed. The probe disclosed by the invention shows the characteristics of rapid blood clearance and low non-specific tissue retention in vivo, and shows specific uptake at a tumor part, so that the potential of the probe as a tumor imaging agent is proved. The probe keeps long-term stability in a physiological environment, provides a material basis for targeted radiotherapy by combining with the characteristics of therapeutic nuclides, and realizes the functions of diagnostic imaging and radiotherapy.

Described herein are methods of treating a solid tumor in a subject comprising administering to the subject a low dose of a targeted radiotherapy (TRT) agent, waiting for a period of time from 1 to 60 days, and after waiting, administering to the subject a chimeric antigen receptor (CAR) T cell therapy.

To provide compositions, kits, and methods for the diagnosis and treatment of prostate cancer. [Solution] Compositions, kits and methods for treating and detecting cancer, and more particularly, radiolabeled conjugates used for targeted radiotherapy for cancer patients, are provided herein. The present invention provides, for example, a cancer-targeting compound for treating cancer cells overexpressing PSMA, wherein the compound comprises a radioisotope, a chelating agent and a PSMA-targeting moiety, the PSMA-targeting moiety being linked to the chelating agent.

The embodiment of the invention provides a webpage-based radiotherapy CBCT registration data analysis method and related equipment, and belongs to the technical field of data management. The method comprises the following steps: responding to input screening condition information; screening the plurality of initial radiotherapy CBCT registration data according to the screening condition information to obtain at least one target radiotherapy CBCT registration data; performing error analysis on the at least one target radiotherapy CBCT registration data, and if it is determined that the first target radiotherapy CBCT registration data is abnormal, performing highlight display on the first target radiotherapy CBCT registration data; the first target radiotherapy CBCT registration data is any target radiotherapy CBCT registration data. According to the embodiment of the invention, intelligent retrieval and matching are carried out on the plurality of initial radiotherapy CBCT registration data through a condition-driven screening mechanism, and a user is prompted to focus on the abnormal target radiotherapy CBCT registration data through highlight display, so that the efficiency of extracting the radiotherapy CBCT registration data meeting the requirements is improved, and meanwhile, the intuition of abnormality recognition can be enhanced.

The invention relates to an X-ray controllable activation nanoparticle as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The technical problems that in the existing radiotherapy sensitization process, NO whole body delivery lacks tumor selectivity, toxicity is large, and radiotherapy specific release cannot be achieved are solved. The nanoparticle comprises a polymer carrier, a nitric oxide donor entrapped in the polymer carrier and a targeting molecule modified on the surface of the nanoparticle, the polymer PEG-PCL carrier is an amphiphilic block copolymer; the nitric oxide donor is BNN6; the targeting molecule is a GRP78 targeting peptide. The nanoparticle is a delivery system capable of realizing GRP78 targeting and X-ray activated NO release at the same time, can actively target radiotherapy to resist tumors, and can trigger to release NO only under X-ray irradiation so as to realize safe and efficient radiotherapy sensitization.

The present invention relates to isolated antibody fragments and more in particular single-domain antibodies that have affinity for tumor antigens and tumor-associated antigens such as HER2. Also provided herein is a pharmaceutical composition comprising the antibody fragment, the CAR immune cell comprising said fragment, or the nucleic acid or vector encoding said antibody fragment for use in the prevention and / or treatment of a tumor or cancer, or for use in adoptive immunotherapy such as CAR-T-cell therapy or targeted radiotherapy.

This invention provides a method, apparatus, and electronic device for determining radiotherapy plans based on nanodosimetry, relating to the field of radiation technology. The method for determining radiotherapy plans based on nanodosimetry includes: obtaining time-varying distribution data of nanodosimetry within a mixed heavy ion beam radiation field using a simulation platform; wherein the mixed heavy ion beam radiation field corresponds to a candidate radiotherapy plan at an ultra-high dose rate for the target patient; the ultra-high dose rate is a dose rate greater than a target threshold; based on the time-varying distribution data of nanodosimetry, obtaining a dose correction factor corresponding to the candidate radiotherapy plan using a cell survival fraction model; and adjusting the candidate radiotherapy plan according to the dose correction factor to obtain the target radiotherapy plan for the target patient. This invention can establish an accurate and reliable biophysical model of a heavy ion ultra-high dose rate radiation field, enabling the determination of precise radiotherapy plans based on this biophysical model.

The present disclosure provides, inter alia, a conjugate that can be radiolabeled and administered to a subject for diagnosing and treating a cancer.

The invention relates to the technical field of tumor imaging and targeted therapy, and particularly discloses a FAP-targeted cyclopeptide compound which comprises a compound with a structural formula as shown in at least one of a formula X-1, a formula X-2, a formula X-3, a formula X-4, a formula X-5, a formula X-6 or a formula X-7. The compound has high affinity to FAP protein, shows remarkable uptake and long-acting retention characteristics in tumor tissues, is suitable for radiodiagnosis and targeted radiotherapy of FAP high-expression cancers, and has a wide clinical application prospect.

Systems and methods for detecting and diagnosing faults in a radiotherapy system, such as a fault related to a dynamic leaf guide (DLG), are discussed. An exemplary predictive maintenance system includes a processor configured to receive machine data indicative of configuration and operation of a DLG in a target radiotherapy machine, apply a trained deep learning model to the received machine data, and detect and diagnose a DLG fault. The predictive maintenance system can train the deep learning model using data sequences constructed from the received machine data of the one more normal DLGs and the one or more faulty DLGs. Diagnosis of the DLG fault in the target radiotherapy machine includes classifying the DLG faults into different fault types or different fault severities.

A pharmacological composition contains a complex having a structurally modified RGD polypeptide a radionuclide. This pharmacological composition is useful for diagnosis or treatment of the integrin αvβ3-positive tumors. The pharmacological composition may further contain an immunotherapeutic medicament and an optional nanoantibody molecular imaging probe. Treatment with a PD-L1 blockade after the targeted radioactive therapy can archive the optimal synergic efficacy. Moreover, with administration of PD-1 or PD-L1 nanoantibody molecular imaging probe, expression of PD-1 or PD-L1 in the tumor after targeted radiotherapy can be observed.

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and / or mammalian tissue overexpressing prostate specific membrane antigen ("PSMA") where the compounds are represented by the following Formulas (I), or a pharmaceutically acceptable salt thereof (IA), or a pharmaceutically acceptable salt thereof (II), or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.